[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocarditis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocarditis":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,60,90,126,161,188,221,244,267,294,318,339,358,376,402,428,453,480,507,535,562,589,630,650,683],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":38,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100598885","eacvi-study-on-multimodality-cardiovascular-imaging-of-inflammatory-cardiovascular-diseases-100598885",false,"NCT07077304","EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","EACVI-INFLAME","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to provide informed non-opposition\n3. Referred for a CMR and\u002For nuclear imaging exam\n\nAND a suspicion of one of the following ICARDs :\n\n1. Suspected Myocarditis (acute or chronic, and whatever the aetiologies)\n2. Suspected Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA)\n3. Suspected Tako-Tsubo\n4. Suspected Pericarditis (acute or chronic, and whatever the aetiologies)\n5. Suspected Connective tissue disease with cardiovascular involvement:\n\n   * Systemic sclerosis\n   * Systemic lupus erythematosus\n   * Antiphospholipid syndrome\n   * Idiopathic inflammatory myopathies\n   * Rheumatoid arthritis, spondylarthritis\n6. Suspected Vasculitis with cardiovascular involvement:\n\n   * Small-vessel vasculitis (ANCA…)\n   * Large vessel vasculitis (Behcet disease, Takayasu…)\n7. Suspected Inflammatory disease with cardiovascular involvement:\n\n   * Sarcoidosis\n   * Still disease\n\nExclusion Criteria:\n\n1. Inability to provide non-opposition\n2. History of heart transplant","ALL","18 Years",{"count":20,"type":21},5000,"ESTIMATED","OBSERVATIONAL","Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of the heart. ICARDs are associated with increased cardiovascular morbidity and mortality, independently of traditional risk factors, via multiple pathophysiological mechanisms.\n\nDiagnosis and prognosis are challenged by the heterogeneity of clinical presentations. Multimodality cardiovascular imaging - including cardiovascular magnetic resonance (CMR), transthoracic echocardiography, and positron emission tomography (PET) - plays a central role in detecting and characterizing inflammatory involvement, and may offer prognostic insights.\n\nGiven the limited data on the diagnostic and prognostic utility of these imaging modalities in ICARDs, the EACVI-INFLAME study aims to assess the prevalence of confirmed cardiovascular involvement in patients with suspected or established ICARDs undergoing CMR and\u002For cardiac PET in a multicentric international cohort.",[25,26,27,28,29,30,31,32,33,34,35,36,37],"Myocarditis","ANCA Associated Vasculitis","Pericarditis","Systemic Sclerosis","Systemic Lupus Erythematosus","Idiopathic Inflammatory Myopathies","Rheumatoid Arthritis","Spondylarthritis","Behcet Disease","Takayasu Arteritis","Sarcoidosis","Still Disease","Tako Tsubo Cardiomyopathy",[39,40,41,42,43,44,45,46],"Cardiovascular disease","Auto-immune disease","Auto-inflammatory disease","Rheumatic disease","CMR","PET","multimodality imaging","ICARD","RECRUITING","2026-06-03",{"date":50,"type":51},"2026-06-05","ACTUAL",{"date":53,"type":51},"2025-11-19",{"date":55,"type":21},"2028-10-30",{"name":57,"class":58},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":61,"slug":62,"hasResults":12,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":68,"targetDuration":70,"studyType":22,"phases":4,"briefSummary":71,"conditions":72,"keywords":77,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":59},"100638834","multimodal-magnetic-resonance-imaging-in-cardiovascular-disease-100638834","NCT07617844","Multimodal mAgnetic Resonance imaGIng in Cardiovascular Disease","Multimodal-MRI in Cardiovascular Diseases","MAGIC","Inclusion Criteria:\n\n* Aged 18 years and older, with no gender restrictions.\n\nClinically suspected or confirmed cardiovascular disease (including but not limited to ischemic heart disease, non-ischemic cardiomyopathy, myocarditis, valvular disease, etc.), requiring a cardiac magnetic resonance (CMR) examination to determine the etiology or evaluate myocardial tissue characteristics.\n\nNo contraindications to magnetic resonance examination, and able to cooperate with breath-holding instructions.\n\nVoluntarily participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Absolute contraindications: Implantation of non-MRI compatible metallic foreign bodies (e.g., old pacemakers, implantable cardioverter-defibrillators \\[ICD\\], aneurysm clips, etc.).\n\nRelative contraindications: Severe claustrophobia, unable to complete the examination despite communication.\n\nSevere renal insufficiency.\n\nSpecial populations: Pregnant or lactating women.\n\nPresence of severe arrhythmias (e.g., persistent atrial fibrillation) leading to severely impaired magnetic resonance signal acquisition, rendering the image quality inadequate for diagnosis.\n\nPoor expected compliance: Unable to complete follow-up, or deemed unsuitable for enrollment by the investigator for other reasons.",{"count":69,"type":21},2000,"3 Years","This single-center, prospective, observational cohort study aims to evaluate the clinical application value of multi-modal cardiovascular magnetic resonance (CMR) imaging in patients with cardiovascular diseases (CVD).\n\nWhile traditional imaging methods have limitations in fully evaluating myocardial tissue characteristics, multi-modal CMR offers a comprehensive, non-invasive \"one-stop\" assessment. It can simultaneously evaluate heart structure, function, tissue features (such as fibrosis and edema), and hemodynamics.\n\nThe study plans to enroll patients with suspected or confirmed CVD. Participants will undergo a comprehensive multi-modal CMR scan (including Cine, T1\u002FT2 mapping, Late Gadolinium Enhancement, and 4D flow sequences) as part of their evaluation. By tracking clinical outcomes, the study seeks to establish a standardized imaging assessment system to improve the early detection, accurate diagnosis, risk stratification, and prognostic prediction for various types of cardiovascular diseases.",[73,74,75,25,76],"Cardiovascular Diseases","Ischemic Heart Disease (IHD)","Cardiomyopathy","Heart Valve Diseases",[78,79,80],"Cardiac Magnetic Resonance","Magnetic Resonance Imaging","Multimodal Imaging","2026-05-26",{"date":83,"type":51},"2026-06-01",{"date":85,"type":51},"2026-01-01",{"date":87,"type":21},"2028-12-31",{"name":89,"class":58},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100289553","mayo-avc-registry-and-biobank-100289553","NCT03049254","Mayo AVC Registry and Biobank","Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy","Inclusion Criteria:\n\n* Patients with a diagnosis of a non-MI SCA who survived\n* Patients with a non-MI SCD\n* Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected\n* Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)\n\nExclusion Criteria:\n\n* Patients with a clear, unambiguous known cause of SCA or SCD such as myocardial infarction or heart failure secondary to ischemic heart disease\n* Significant coronary artery disease (Epicardial coronary artery stenosis \\>50%) which can explain degree of LV dysfunction\n* Those unwilling to provide written consent or assent",true,{"count":99,"type":21},1000,"Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death.\n\nThe Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history of AVC or sudden cardiac death which may be due to AVC, from the US and UK. Family members who are blood-relatives will also be invited, including those who do not have the condition. Data collected include symptoms, ECG, echocardiographic, MRI, Holter, loop recorder, biopsies, exercise stress testing, blood, buccal and saliva samples.\n\nObjectives of the study:\n\n1. Discover new genes or altered genes (variants) which cause AVC\n2. Identify biomarkers which predict (2a) disease onset, (2b) disease progression, (2c) and the likelihood of arrhythmia (ventricular, supra-ventricular and atrial fibrillation)\n3. Correlate genotype with phenotype in confirmed cases of AVC followed longitudinally using clinical, electrocardiographic and imaging data.\n4. Characterize desmosomal changes in buccal mucosal cells with genotype and validate with gold-standard endomyocardial biopsies",[102,103,104,73,105,106,107,108,109,110,35,111,112,25,113,114,115],"Arrhythmogenic Right Ventricular Cardiomyopathy","Cardiomyopathies","Heart Diseases","Sudden Cardiac Arrest","Sudden Cardiac Death","Arrhythmogenic Right Ventricular Dysplasia","Arrhythmogenic Ventricular Cardiomyopathy","Familial Dilated Cardiomyopathy","Cardiovascular Abnormalities","Cardiac Arrhythmia","Cardiac Sarcoidosis","Inflammatory Cardiomyopathy","Ventricular Tachycardia","Right Ventricular Outflow Tract Ventricular Tachycardia","2026-04-22",{"date":118,"type":51},"2026-04-27",{"date":120,"type":51},"2018-02-09",{"date":122,"type":21},"2027-03",{"name":124,"class":58},"Mayo Clinic",2,{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":136,"phases":137,"briefSummary":139,"conditions":140,"keywords":143,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100528279","phase-3-cmp-mythic-trial-and-registry---cardiomyopathy-with-myocarditis-therapy-with-colchicine-100528279","NCT06158698","CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine","Single-blinded Randomized Investigator-initiated Controlled Trial to Assess the Efficacy of Colchicine to Treat Patients With Cardiomyopathy With Myocarditis (Chronic Inflammatory Cardiomyopathy)","CMP-MYTHiC","Inclusion Criteria Trial and Registry:\n\n* Males and females with Infl-CMP associated with VA (including high PVC burden), reduced LVEF, or significantly increased levels of natriuretic peptides.\n* Patients of 18 years or older\n* Evidence of myocardial inflammation on CMRI (using 2018 Lake Louis criteria) or FDG-PET performed in the 3 months before randomization to be included in the trial OR in the last 12 months before for the registry.\n* Presence of any of the following characteristics and if symptoms have been present for more than 1 month:\n* Mono-morphic or polymorphic PVC burden of ≥3000 in 24 hours, or NSVTs (defined as \\>3 more consecutive beat lasting \\\u003C30 seconds) or evidence of sustained ventricular tachycardias (SVT).\n* Reduced LVEF on echocardiogram (\\\u003C50%) or on CMRI (\\\u003C60%)-. Increased N-terminal pro-B-type natriuretic peptide (NT- proBNP) concentration of 1000 pg\u002FmL or more, or a B-type natriuretic peptide (BNP) concentration of 200 pg\u002FmL or more\n* Persistence of increased high-sensitivity troponin levels above the upper reference limit (URL) after at least 2 months from the first assessment and at least a mono-morphic or polymorphic PVC burden of ≥1000 in 24 hours.\n\nExclusion Criteria Registry:\n\n* Proven history of myocardial infarction with evidence of ischemic scar on echocardiogram or CMRI,\n* Significant flow-limiting coronary artery disease (stenosis above 50%) on invasive coronary angiography or computed tomography (CT) coronary angiography,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, or to specific causes (i.e. amyloidosis or hypertrophic cardiomyopathy)\n* Known systemic autoimmune disorder (the exception will be for patients with systemic autoimmune disease or isolated cardiac sarcoidosis with a family history of cardiomyopathy, myocarditis, or arrhythmias, where overlap between an autoimmune event and a genetic background can occur). These patients will undergo genetic tests. Patients with autoimmune systemic disorders and isolated cardiac sarcoidosis with positive genetic tests for MCVG will be included in the registry.\n* Previous history of cardiac surgery for instance correction of congenital heart disease or a valve repair\u002Freplacement\n* Known chronic infective disease, such as HIV infection or tuberculosis\n* Participants involved in another clinical trial, defined by the participation in a clinical trial in which an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer;\n* Any other significant disease or disorder which (expected life expectancy \\\u003C12 months), in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial.\n\nExclusion Criteria Trial :\n\n* Proven history of myocardial infarction with evidence of ischemic scar on echocardiogram or CMRI,\n* Significant flow-limiting coronary artery disease (stenosis above 50%) on invasive coronary angiography or computed tomography (CT) coronary angiography,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, or to specific causes (i.e. amyloidosis or hypertrophic cardiomyopathy)\n* Known systemic autoimmune disorder (the exception will be for patients with systemic autoimmune disease or isolated cardiac sarcoidosis with a family history of cardiomyopathy, myocarditis, or arrhythmias, where overlap between an autoimmune event and a genetic background can occur). These patients will undergo genetic tests. Patients with autoimmune systemic disorders and isolated cardiac sarcoidosis with positive genetic tests for MCVG will be included in the registry.\n* Previous history of cardiac surgery for instance correction of congenital heart disease or a valve repair\u002Freplacement\n* Known chronic infective disease, such as HIV infection or tuberculosis\n* Participants involved in another clinical trial, defined by the participation in a clinical trial in which an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer;\n* Any other significant disease or disorder which (expected life expectancy \\\u003C12 months), in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial.\n* Women with childbearing potential (this exclusion criterion is due to insufficient human information regarding the embryofoetal risk with colchicine)\n* Current symptomatic atrial arrhythmias (including persistent atrial fibrillation) associated with LV dysfunction,\n* Advance heart failure (NYHA III or need for inotropes including levosimendan), or recurrent VA despite previous catheter ablation,\n* Known systemic autoimmune disorder or other conditions at the time of randomization where immunosuppression is assumed useful (i.e. cardiac sarcoidosis),\n* Patients already on chronic immunosuppressive therapies (including colchicine) or in whom immunosuppressive therapy is deemed necessary\n* Contraindication to colchicine, including allergies to this medication and its excipients (i.e., lactose and sucrose),\n* Impaired renal function (eGFR\\\u003C30 ml\u002Fmin\u002F1.73m2),\n* Known history of hepatic cirrhosis or transaminase levels at baseline \\> x3-fold the URL\n* Patients with peripheral eosinophilia (eosinophil count \\>10% of the leukocytes) or known hypereosinophilic syndrome at the time of randomization.\n* Severe gastrointestinal insufficiency (for instance, malabsorption syndrome, severe chronic diarrhea)\n* Women during breastfeeding",{"count":135,"type":21},80,"INTERVENTIONAL",[138],"PHASE3","Two-parallel groups randomized, single-blinded, multi-center phase III controlled trial in patients with chronic inflammatory cardiomyopathy to assess the efficacy of colchicine and associated prospective registry to assess the prognostic value of positive genetic testing in this population.",[103,25,113,141,142],"Heart Failure","Ventricular Arrythmia",[144,145,146,147,148,149,150],"treatment","trial","colchicine","registry","inflammation","outcome","genetic testing","2026-04-15",{"date":153,"type":51},"2026-04-20",{"date":155,"type":51},"2023-11-14",{"date":157,"type":21},"2028-05-02",{"name":159,"class":58},"Niguarda Hospital",10,{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":170,"studyType":22,"phases":4,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":59},"100409500","the-heart-hive---cardiomyopathy-study-100409500","NCT04612296","The Heart Hive - Cardiomyopathy Study","A Longitudinal Observational Study of Self-reported Cardiomyopathy in the Heart Hive","Inclusion Criteria:\n\n* Adult (age 18 and over),\n* Males and Females,\n* Capacity to provide informed consent,\n* Patients with a confirmed diagnosis of cardiomyopathy or myocarditis,\n* People with a family history of cardiomyopathy confirmed in a first or second degree relative.\n\nNote: Pregnant women are eligible. This study is observational and entirely separate from clinical care.\n\nExclusion criteria:\n\n* Patients who lack capacity to consent for themselves,\n* Vulnerable groups (e.g. those under 18, prisoners, those in a dependent relationship, the mentally ill).\n* Patients with a confirmed history of coronary artery disease:\n* who have been informed by their treating physician that their cardiomyopathy is secondary to their coronary artery disease, or\n* who have undergone previous percutaneous coronary intervention or coronary bypass surgery\n* History of primary valvular heart disease or congenital heart disease\n* Severe, untreated or untreatable hypertension (systolic blood pressures routinely \\>180 mm Hg and\u002For diastolic blood pressures \\>120 mm Hg)",{"count":169,"type":21},10000,"50 Years","This is an online registry and database of patients with cardiomyopathy and myocarditis, coupled with an observational study of cardiomyopathies.",[103,25],[174,175,176,177,178],"Takotsubo","Dilated cardiomyopathy","hypertrophic cardiomyopathy","ARVC","ACM","2026-03-24",{"date":181,"type":51},"2026-03-27",{"date":183,"type":51},"2019-11-09",{"date":185,"type":21},"2027-09",{"name":187,"class":58},"Imperial College London",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":17,"minAge":195,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":136,"phases":198,"briefSummary":200,"conditions":201,"keywords":206,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":220},"100630068","routine-versus-provisional-distal-perfusion-catheter-placement-in-patients-undergoing-mechanical-circulatory-support-100630068","NCT07482865","Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support","PERFUSE-MCS","Inclusion Criteria:\n\n* Patients aged 19 years old\n* Cardiogenic shock requiring mechanical circulatory support through femoral artery approach\n* Subject who can verbally confirm understandings of risks and benefits of receiving distal perfusion catheter insertion and he\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study related procedure.\n* Under the critically-ill clinical circumstance (unclear consciousness of patient), legally authorized representative can provide written informed consent prior to any study related procedure.\n\nExclusion Criteria:\n\n* Apparent symptoms and sign of acute limb ischemia immediately after mechanical circulatory support insertion\n* Significant coagulopathy precluding invasive procedure due to high risk of bleeding\n* Pregnant women, women with potential childbearing, or lactating women\n* Irreversible limb ischemia requiring interventional procedures or surgery at the time of MCS insertion\n* Previous history if femoral-femoral bypass grafting or femoral-popliteal bypass grafting\n* Previous history of limb amputation\n* Unwilling or unable to obtain informed consent from the participant or legally authorized representative","19 Years",{"count":197,"type":21},500,[199],"NA","A prospective, multi-center, open label, randomized controlled, superiority trial to compare clinical outcomes between routine distal perfusion catheter (DPC) insertion versus provisional distal perfusion catheter (DPC) insertion in the occurrence of sign or symptom of acute limb ischemia in patients undergoing mechanical circulatory support (MCS) through femoral artery approach.",[202,203,204,25,205],"Cardiogenic Shock","Acute Myocardial Infarction of Inferior Wall","Congestive Heart Failure","Acute Limb Ischemia",[202,207,208,204,209],"Distal perfusion catherter","Acute Myocardial Infarction","Limb ischemia","NOT_YET_RECRUITING","2026-03-18",{"date":213,"type":51},"2026-03-20",{"date":215,"type":21},"2026-05-01",{"date":217,"type":21},"2030-10-31",{"name":219,"class":58},"Samsung Medical Center",6,{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":97,"sex":17,"minAge":229,"maxAge":4,"enrollmentInfo":230,"targetDuration":232,"studyType":22,"phases":4,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":59},"100442793","covid-19-vaccine-induced-inflammatory-heart-disease-prevalence-registry-100442793","NCT05046002","COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry","COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry (COVID-VIHPR)","COVID-VIHPR","Inclusion Criteria:\n\n1. All patients eligible for vaccination with a COVID-19 vaccine,\n2. At least one cardiac symptom of suspected myocarditis\u002Fpericarditis within 42 days of receiving a COVID-19 vaccination. The clinical symptoms include chest pain, pressure, or discomfort; dyspnea, shortness of breath\u002Fdyspnea\u002Fpain with breathing, palpitations, diaphoresis, syncope, or sudden death.\n\n   OR At least two non-specific symptoms within 42 days of receiving a COVID-19 vaccination. These symptoms include fatigue, abdominal pain, dizziness or syncope, edema, or cough.\n\n   OR No symptoms, but abnormal histopathology or a combination of abnormal cardiac biomarkers with abnormal cardiac imaging (echo or MRI)\n3. At least one of the following:\n\n   1. Elevations in Troponin T, Troponin I, or CK-MB (above threshold of normal)\n   2. Abnormal MRI (per Brighton Criteria Case Definitions)\n   3. Any new or worsening cardiac arrhythmias on ECG or telemetry or Holter monitor (per Brighton Criteria Case Definitions) including those that normalize on recovery.\n   4. Abnormal Echocardiographic findings (per Brighton Criteria Case Definitions, see Appendix 2 and 3)\n   5. Physical exam finding: Pericardial friction rub or pulsus paradoxus\n   6. Pericardial fluid or inflammation by imaging (echo, MRI, or CT) or at least one of the following elevated biomarkers of inflammation: ESR, CRP, hs-CRP, or D-Dimer.\n   7. Enlarged heart on chest radiograph.\n   8. Histopathologic examination of myocardial tissue (autopsy or endomyocardial biopsy) showed myocardial inflammation\n\nExclusion Criteria:\n\n1. Clear alternative diagnosis or explanation for the symptoms and findings (e.g. infectious myocarditis such as Lyme carditis). Note: Work-up of alternative diagnosis is dependent on clinical presentation e.g. Lyme carditis (e.g. endemic area, season, bullseye rash) or autoimmune heart disease (e.g. arthritis, rash, recurrence).\n2. Symptoms after 42 days of vaccination.","5 Years",{"count":231,"type":21},400,"4 Years","Myocarditis and pericarditis are inflammatory diseases of the myocardium and pericardium, and can be related to different causes, including vaccines. In the past, some people developed inflammatory heart disease after receiving a live or inactive virus vaccine (smallpox vaccine or flu vaccine). Myocarditis was also seen in people with COVID-19. More recently, many countries reported that some people have developed an inflammatory condition of the myocardium or pericardium after receiving a vaccine for COVID-19.\n\nAfter the COVID-19 vaccination campaigns, doctors have noticed more people presenting to the Emergency Department with chest pain and shortness of breath after receiving the vaccine, symptoms that resemble myocarditis or pericarditis. These symptoms may start between 2 to 10 days following vaccination and are frequently noticed after the second dose of the vaccines. While pericarditis seems to affect people of various age groups and gender, myocarditis is more commonly seen in young males.\n\nThe study will consist of two components. 1) The vaccine-induced inflammatory heart disease database will be established. There will be a retrospective chart review looking at vaccine myocarditis\u002Fpericarditis (Brighton Criteria Levels 1-3).\n\n2\\) There will be a prospective, pragmatic design case-control study for vaccine myocarditis\u002Fpericarditis. Follow-up telephone interview will be conducted at 6 months, 12 months and yearly up to 4 years. A record search will also be performed at 6 months, 12 months and yearly for 4 years.\n\nThe retrospective component of the study will be conducted by identifying patients previously diagnosed with this condition at participating centres.",[25,27],"2026-01-26",{"date":237,"type":51},"2026-01-28",{"date":239,"type":51},"2021-08-11",{"date":241,"type":21},"2026-12-31",{"name":243,"class":58},"Ottawa Heart Institute Research Corporation",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":97,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":59},"100620209","the-application-of-t1-mapping-in-real-world-100620209","NCT07354646","The Application of T1 Mapping in Real-World","The Landscape of T1 Mapping for Disease Profiling in a Real-World Cohort","Inclusion Criteria:\n\n1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines.\n2. Specific disease categories include:\n\n   * Cardiomyopathies (HCM, DCM, RCM, ACM)\n   * Infiltrative disorders (cardiac amyloidosis, Fabry disease)\n   * Inflammatory conditions (acute\u002Fchronic myocarditis)\n   * Ischemic heart disease (acute\u002Fchronic MI)\n   * Valvular heart disease (aortic stenosis)\n   * Arrhythmic conditions (atrial fibrillation)\n   * Metabolic disorders (iron-overload)\n   * Neoplastic conditions (cardiac tumors)\n   * Congenital heart disease\n   * Post-transplant evaluation\n3. All diagnoses must be confirmed using established guideline-based criteria:\n\n   * Echocardiographic parameters meeting disease-specific cutoffs\n   * Cardiac MRI findings consistent with current consensus criteria\n   * Laboratory biomarkers supporting respective diagnoses\n   * Histopathological confirmation when clinically indicated\n\nExclusion Criteria:\n\n* Presence of multiple cardiomyopathy diseases or risk factors simultaneously\n* Contraindications to CMR examination\n* Poor image quality precluding accurate T1 mapping analysis\n* Incomplete clinical data for definitive diagnosis confirmation\n* Pregnancy or lactation\n* Inability to provide informed consent",{"count":69,"type":21},"The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are:\n\nWhat are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler \"native T1\" measurement (without contrast dye) instead of the more complex \"ECV\" measurement (which requires contrast dye) for diagnosis?\n\nPatients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping",[254,255,256,257,25],"Myocardial Infarction (MI)","Hypertrophic Cardiomyopathy (HCM)","Dilated Cardiomyopathy (DCM)","Arrhythmogenic Cardiomyopathy","2026-01-12",{"date":260,"type":51},"2026-01-21",{"date":262,"type":51},"2020-03-01",{"date":264,"type":21},"2026-12-01",{"name":266,"class":58},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":274,"targetDuration":229,"studyType":22,"phases":4,"briefSummary":276,"conditions":277,"keywords":281,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":59},"100396593","improving-cardiovascular-risk-stratification-using-t1-mapping-in-general-population-100396593","NCT04444128","IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION","IMPReSSION","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. 18 years of age and over\n3. Absence of a valid clinical indication for CMR, and\u002For known or clinically relevant cardiac disease\n\nExclusion Criteria:\n\n* accepted contraindications for a contrast-enhanced CMR study (in line with MRI safety and SmPC for contrast agent)",{"count":275,"type":21},6000,"Magnetic properties of myocardial tissue change in the presence of disease. This is detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable imaging measures for myocardial tissue characterisation. Despite similar principles, the measurements differ considerably between different sequences, vendors and field strengths, yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy, relationships with clinical characteristics, cardiovascular risk factors, routine cardiac imaging parameters, and prognosis. A further unknown relates to separation between healthy myocardium and subclinical disease in subgroups of patients with suspected cardiac involvement. Examples include patients with possible inflammation, such as in patients with a recent COVID-19 infection or vaccination. Anticipated recruitment of a total of 3000 subjects, with 1500 subjects per field strength (1.5 and 3.0 Tesla).",[25,141,278,279,280],"Myocardial Fibrosis","Vascular Inflammation","Long COVID Syndrome",[282,283,284],"Inflammation","Remodeling","vascular inflammation","2026-01-02",{"date":287,"type":51},"2026-01-06",{"date":289,"type":51},"2016-11-15",{"date":291,"type":21},"2030-06-30",{"name":293,"class":58},"Johann Wolfgang Goethe University Hospital",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":17,"minAge":302,"maxAge":18,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":314,"leadSponsor":316,"locationsCount":4},"100606468","outcome-of-clinical-phenotypes-of-pediatric-myocarditis-at-assiut-university-children-hospital-100606468","NCT07175948","Outcome of Clinical Phenotypes of Pediatric Myocarditis at Assiut University Children Hospital","Outcome of Different Clinical Phenotypes of Myocarditis in Children Admitted to Assiut University Children Hospital","PED-MYO","Inclusion Criteria:\n\n* • Children aged between 1 to 18 years.\n\n  * Children diagnosed with myocarditis based on clinical presentation, echocardiography, and cardiac biomarkers, ECG and MRI (if available)\n\nExclusion Criteria:\n\n* • Children with congenital heart disease.\n\n  * Known cardiomyopathy unrelated to myocarditis.","1 Year",{"count":304,"type":21},100,"This study aims to investigate the clinical phenotypes, management approaches, and outcomes of myocarditis in children admitted to Assiut University Children's Hospital. Myocarditis is an inflammatory disease of the heart muscle that can present in different clinical forms, including acute, fulminant, chronic active, and chronic persistent types. These forms vary in severity, treatment needs, and long-term outcomes.\n\nChildren aged 1-18 years who are diagnosed with myocarditis based on clinical findings, cardiac biomarkers, echocardiography, and electrocardiography (with MRI when available) will be included. Patients with congenital heart disease or cardiomyopathy unrelated to myocarditis will be excluded.\n\nThe study will follow eligible patients prospectively over a 12-month period. Detailed clinical assessment, laboratory tests, echocardiographic findings, and management strategies will be recorded. Special attention will be given to the role of corticosteroids and intravenous immunoglobulin (IVIG) in treatment. Outcomes including recovery of cardiac function, need for intensive care, and survival will be assessed.\n\nBy analyzing the clinical presentation, treatment, and prognosis of different myocarditis phenotypes, this study aims to improve the understanding of disease patterns in children and provide evidence to guide future management.",[25,307],"Myocarditis Acute",[309,202],"Viral Myocarditis","2025-09-14",{"date":312,"type":51},"2025-09-16",{"date":83,"type":21},{"date":315,"type":21},"2027-08-01",{"name":317,"class":58},"Assiut University",{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":220},"100520744","role-of-novel-ilr-in-the-management-of-pvcs-100520744","NCT06060548","Role of Novel ILR in the Management of PVCs","Role of a Novel Implantable Loop Recorder in the Management of Premature Ventricular Contractions","Inclusion Criteria:\n\n* Patients \\> 18 years of age\n* Have a Medtronic LINQ II ILR\n* Willing and able to give written informed consent\n\nExclusion Criteria:\n\n* History of myocardial infarction\n* Significant flow-limiting coronary artery disease (≥50% stenosis) on invasive coronary angiography or Computed tomography angiography (CTA).\n* History of cardiac arrest\n* With existing implantable defibrillators\n* Currently pregnant",{"count":326,"type":21},50,"This prospective, observational study is a single center clinical registry of patients referred for management of symptomatic or asymptomatic Premature Ventricular Contractions (PVCs). Subjects will be followed through 12 months. The study will enroll approximately 50 patients.",[329,25],"PVC - Premature Ventricular Contraction","2025-08-27",{"date":332,"type":51},"2025-08-28",{"date":334,"type":51},"2022-04-20",{"date":336,"type":21},"2025-12",{"name":338,"class":58},"Kansas City Heart Rhythm Research Foundation",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":59},"100451457","myocarditis-causing-premature-ventricular-contractionsinsights-from-the-maveric-registry-100451457","NCT05158751","Myocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC Registry","MAVERIC","Inclusion Criteria:\n\n* Patients \\> 18 years of age with mono-morphic or polymorphic PVC burden of ≥5000 in 24 hours.\n* Non-sustained VT was defined as ≥3 more consecutive beats lasting \\\u003C30 seconds\n\nExclusion Criteria:\n\n* History of myocardial infarction,\n* Significant flow-limiting coronary artery disease (≥50% stenosis) on invasive coronary angiography or CT angiography,\n* History of revascularization,\n* Significant symptomatic atrial arrhythmias associated with LV dysfunction,\n* Severe valvular disease,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs,\n* History of cardiac arrest,\n* History of channelopathies or inherited arrhythmias.",{"count":304,"type":21},"To assess potential link between unrecognized myocardial inflammation (myocarditis) and premature ventricular contractions (PVCs) associated with and without reduced Left ventricular ejection fraction (LVEF) through comprehensive diagnostic work up.",[25,349,350],"Premature Ventricular Contractions","Ventricular Tachycardia (VT)",{"date":352,"type":51},"2025-09-04",{"date":354,"type":21},"2026-01",{"date":356,"type":21},"2026-05",{"name":338,"class":58},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":373,"leadSponsor":374,"locationsCount":375},"100449964","the-orchestrate-myocarditis-registry-100449964","NCT05139329","The ORCHESTRATE-Myocarditis Registry","Observational Registry of Ischemia Negative Chest Pain as the Presentation of Underlying Myocarditis: the ORCHESTRATE-Myocarditis Registry","Inclusion criteria\n\n1. Age \\>18 years\n2. Patients with a presentation of typical or atypical chest pain (ICD-10 Code R07.89, R07. 9)\n3. Patients with a negative ischemic workup: (including Coronary Artery Calcium Scoring\u002FCTA, MPI, Nuclear Stress test, LHC\u002Fangiography showing anything greater than \"non-obstructive CAD\")\n\nExclusion criteria\n\n1. Patients with any evidence of positive ischemic workup as the cause of typical\u002Fatypical chest pain (as seen on Coronary Artery Calcium Scoring\u002FCTA, MPI, Nuclear Stress test, LHC\u002Fangiography)\n2. Previously documented history of Prinzmetal angina or coronary vasospasm\n3. History of prior myocardial infarction\n4. History of any prior CAD with severity greater than \"non-obstructive CAD\" in all 3 coronary arteries\n5. History of LVEF\\\u003C40%\n6. Previously documented history of pericarditis\n7. Previously documented history of costochondritis",{"count":366,"type":21},382,"A retrospective, observational study consisting of patients who presents with typical\u002Fatypical chest pain and have an ensuing negative ischemic evaluation",[25,369,370],"Ischemia","Chest Pain",{"date":332,"type":51},{"date":354,"type":21},{"date":356,"type":21},{"name":338,"class":58},4,{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":97,"sex":17,"minAge":383,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":59},"100547562","cardiomyopathies-and-heart-muscle-diseases-cardiac-imaging-in-the-evaluation-of-myocardial-fibrosis-transition-100547562","NCT06409585","Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition","CHIEFTain","Inclusion Criteria:\n\nHFpEF cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Patients with symptomatic heart failure with preserved ejection fraction as defined by the presence of heart failure symptoms (dyspnoea, reduced exercise tolerance, fatigue), signs (elevated jugular venous pressure, pulmonary crackles, peripheral oedema) as well as echocardiographic features (preserved left ventricular systolic function (\\>50%) and reduced diastolic function with septal e' \\\u003C7cm\u002Fs or lateral e' \\\u003C10cm\u002Fs).\n\nHypertrophic cardiomyopathy cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Established diagnosis of hypertrophic cardiomyopathy: left ventricular wall thickness \\>15mm by any imaging modality without a loading condition to explain the hypertrophy OR\n* Left ventricular wall thickness of \\>13 mm by any imaging modality in the presence of a genetic or non-genetic component, supported by other features including family history, non-cardiac symptoms, ECG changes and laboratory tests.\n\nHypertensive heart disease cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of essential hypertension for at least 1 year with evidence of left ventricular hypertrophy on echocardiography (left ventricular mass index \\>98 g\u002Fm2 and relative wall thickness \\>0.42)\n\nArrhythmogenic cardiomyopathy\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of arrhythmogenic right ventricular cardiomyopathy based on the International Task Force 2010 criteria\n\nMyocarditis cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of myocarditis in the past month defined with the following features\n\n  * Chest pain\n  * Evidence of pericarditis (pericardial rub, ST- segment elevation or pericardial effusion)\n  * Elevated serum troponin\n  * Unobstructed coronary arteries on coronary angiogram OR\n  * Cardiac magnetic resonance imaging evidence of myocarditis (subepicardial or mid-wall late gadolinium enhancement\n\nTakotsubo cardiomyopathy cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of takotsubo cardiomyopathy in the past month as defined by European Society of Cardiology guidelines 2018\n\nCardiac sarcoidosis cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of cardiac sarcoidosis for at least 1 year based on expert consensus opinion with\n\n  * Histological diagnosis from a myocardial biopsy OR\n  * Histological diagnosis of extra-cardiac sarcoid AND\n\nOne or more of following is present\n\n* Steroid +\u002F- immunosuppressant responsive cardiomyopathy or heart block\n* Unexplained reduced LVEF (\\\u003C40%)\n* Unexplained sustained (spontaneous or induced) VT\n* Mobitz type II 2nd degree heart block or 3rd degree heart block\n* Patchy uptake on dedicated cardiac PET (in a pattern consistent with CS)\n* Late Gadolinium Enhancement on CMR (in a pattern consistent with CS)\n* Positive gallium uptake (in a pattern consistent with CS) AND\n* Other causes for the cardiac manifestation(s) have been reasonably excluded\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent.\n* History of claustrophobia or inability to tolerate supine position for the PET\u002FMR or PET\u002FCT scans.\n* Impaired renal function with eGFR of \\\u003C30 mL\u002Fmin\u002F1.73 m2.\n* Women who are pregnant or breastfeeding.\n* Iodine or gadolinium contrast allergy\n* Contra-indication to CT scanning","30 Years","90 Years",{"count":386,"type":21},290,"Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm disturbances and even death. However, a lot of these conditions are still not fully understood and treatment options are limited. We here aim to use a new radioactive dye called 68Ga-FAPI to identify patterns and the activity of heart muscle scarring. This radioactive dye is being used in humans particularly in identifying and monitoring cancers and has shown promise in identifying scarring in the heart as well. This will help us not only understand the underlying disease process and risk stratify these patients but also potentially help us develop new targeted therapies that can affect heart muscle scarring. Participants will undergo a baseline MRI scan using this new dye and a plain MRI scan will repeated 12-18 months after to see if there are any changes in the process.",[389,390,112,391,37,392,25],"Heart Failure With Preserved Ejection Fraction","Hypertrophic Cardiomyopathy","Hypertensive Heart Disease","Arrhythmogenic Right Ventricular Cardiomyopathy 1","2025-08-18",{"date":395,"type":51},"2025-08-19",{"date":397,"type":51},"2023-05-01",{"date":399,"type":21},"2028-01-01",{"name":401,"class":58},"University of Edinburgh",{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":409,"targetDuration":4,"studyType":136,"phases":411,"briefSummary":412,"conditions":413,"keywords":414,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":426,"locationsCount":59},"100599565","efficacy-of-a-myocardial-panel-in-the-management-and-treatment-of-pediatric-myocarditis-100599565","NCT07086144","Efficacy of a Myocardial Panel in the Management and Treatment of Pediatric Myocarditis","Efficacy of a Myocardial Panel (Virological, Bacterial and Autoimmune) in the Management and Treatment of Pediatric Myocarditis Complicated With Arrhythmias or Ventricular Dysfunction","Inclusion Criteria:\n\n* All the consecutive pediatric patients (\\\u003C 18 years old) presenting with myocarditis complicated by arrhythmias or myocardial dysfunction\n\nExclusion Criteria:\n\n* Refused consent to be included in the study given by parents or legal tutors\n* Uncomplicated myocarditis presenting without arrhythmias or myocardial dysfunction",{"count":410,"type":21},30,[199],"The goal of this observational study is to determine the efficacy a of combined management and treatment driven by the systematic determination of viral genome, bacterial serology, and markers of inflammation in pediatric patients (\\\u003C 18 years old) diagnosed with myocarditis complicated by arrhythmias (supraventricular and ventricular tachycardias and heart block) or ventricular dysfunction (left ventricular ejection fraction \\\u003C 50% or right ventricular fractional area change \\\u003C 35%).\n\nThe main question it aims to answer is: Does this panel help resolve arrhythmias or myocardial dysfunction due to myocarditis during hospitalisation and follow-up?\n\nResearchers will compare patients managed and treated in 2024 without applying the myocarditis panel with those enrolled in 2025 who received the panel. Arrhythmias and myocardial dysfunction will be managed in accordance with recent guidelines. Antiviral, antibiotic or immunosuppressive therapies will be implemented in addition to standard therapy when required by the panel.",[25],[415,416,417,418,419],"pediatric myocarditis","Arrhythmias","Myocarditis panel","Etiological therapy","Myocardial dysfunction","2025-07-18",{"date":422,"type":51},"2025-07-25",{"date":424,"type":51},"2024-01-01",{"date":87,"type":21},{"name":427,"class":58},"Azienda Ospedaliero, Universitaria Ospedali Riuniti",{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":17,"minAge":435,"maxAge":4,"enrollmentInfo":436,"targetDuration":438,"studyType":22,"phases":4,"briefSummary":439,"conditions":440,"keywords":441,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":59},"100427295","acute-myocarditis-registry-with-prognostic-histologic-immunologic-biological-imaging-and-clinical-assessment-100427295","NCT04844151","Acute Myocarditis Registry With Prognostic, Histologic, Immunologic, Biological, Imaging and Clinical Assessment","AMPHIBIA","Inclusion Criteria:\n\n* Acute myocarditis confirmed by cardiac magnetic resonance according to Lake Louise modified criteria or by endomyocardial biopsy according to histologic, immunologic and immunohistochemic criteria.\n* affiliation to the French Health Care System \"Sécurité sociale\"\n\nExclusion Criteria:\n\n* Severe valvulopathy\n* Complex congenital cardiopathy\n* Previous heart transplant\n* Known significative coronary disease","15 Years",{"count":437,"type":21},1400,"20 Years","The AMPHIBIA study is an observational ambispective and prospective cohort that aim to describe the histologic, immunologic, biological, imaging, genetic and clinical characteristics of the patients hospitalized for an acute myocarditis and to evaluate their association with prognosis.",[25],[103,442,443,444],"Inflammatory heart disease","Magnetic resonance imaging","Viral","2025-06-03",{"date":447,"type":51},"2025-06-06",{"date":449,"type":51},"2022-01-23",{"date":451,"type":21},"2041-05-01",{"name":57,"class":58},{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":97,"sex":17,"minAge":461,"maxAge":462,"enrollmentInfo":463,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":465,"conditions":466,"keywords":467,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":59},"100584463","geam-study-aims-at-assessing-the-role-of-genetic-testing-in-patients-with-arrhythmic-myocarditis-100584463","NCT06889662","GEAM Study Aims At Assessing the Role of Genetic Testing in Patients with Arrhythmic Myocarditis.","GEAM: Yield of GEnetic Testing in Arrhythmic Myocarditis","GEAM","Inclusion Criteria:\n\nPatients with ventricular arrhythmias (VA+) and without (VA-)\n\n* Diagnosis of myocarditis proven by EMB (ESC criteria) and\u002For CMR (updated Lake Louise criteria)\n* Age ≥ 10 years\n* Baseline ECG telemonitoring\n* Written informed consent Healthy controls\n* Provided a negative known history of myocarditis\n* The sample must have been biobanked as part of the study IMMUNORADAR\n\nExclusion Criteria:\n\nPatients with ventricular arrhythmias (VA+) and without (VA-)\n\n* Obstructive coronary artery disease, or lack of coronary angiography\u002Fcomputed tomography (CT) scan in patients \\>40 years.\n* Absent informed consent.","10 Years","80 Years",{"count":464,"type":21},262,"This study aims to answer multiple unsolved questions in the field of arrhythmic myocarditis.\n\n* Improving the diagnostic work-up. While endomyocardial biopsy (EMB) and cardiac magnetic resonance (CMR) constitute the gold standard diagnostic techniques for myocarditis, the role of genetic testing is still unclear. Identifying the subset of patients with CGVs, will contribute to justifying the application of genetic testing in myocarditis.\n* Generating models for risk prediction. Outcomes and arrhythmic risk stratification remain uncertain for myocarditis. Based on an advanced multimodal work-up, multiparametric risk scores may be created and subsequently validated, in order to predict the arrhythmic risk of specific myocarditis, especially in the case of CGVs.\n* Identifying disease-specific and genotype-specific signatures. Genotype-phenotype associations are expected to benefit from a multimodal and multiparametric approach, in order to allow etiology-specific features in arrhythmic myocarditis. Most of the current signatures are limited to combined EMB-CMR studies. Signatures would likely benefit from implementing additional parameters, including arrhythmia features and myocardial inflammatory status.\n* Tailoring treatment strategies. Transcriptional analysis will identify overexpressed genes associated with myocarditis and arrhythmias, representing a possible therapeutic target. A multimodal and multidisciplinary model will integrate phenotype, genotype, and transcriptional profile for a personalized treatment.",[25,142],[468,469,470],"Arrhythmogenic cardiomyopathy","Ventricular arrhythmias","Myocardial inflammation","2025-03-19",{"date":473,"type":51},"2025-03-21",{"date":475,"type":51},"2025-02-25",{"date":477,"type":21},"2027-12-01",{"name":479,"class":58},"Scientific Institute San Raffaele",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":97,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":489,"conditions":490,"keywords":494,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":4},"100573590","ai-enabled-screening-and-diagnosis-of-cardiomyopathies-using-coronary-cta-100573590","NCT06748261","AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA","Artificial Intelligence-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary Computer Tomography Angiography","Atlantis","Cardiomyopathy cohort:\n\n* Inclusion Criteria:\n\n  1. A clinical diagnosis of cardiomyopathies, including hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, cardiac amyloidosis, myocarditis, arrhythmogenic right ventricular cardiomyopathy, and coronary artery disease\u002Fischemic heart disease.\n  2. At least one CCTA before surgery or implantable device treatment.\n* Exclusion Criteria:\n\n  1. No recorded diagnosis of cardiomyopathy or undetermined type of cardiomyopathy.\n  2. A clinical diagnosis of secondary cardiac abnormalities due to other organic or systemic diseases.\n  3. Surgery or implantable device treatment before CCTA examination.\n\nControl cohort:\n\n* Inclusion Criteria: participants with at least one CCTA examination.\n* Exclusion Criteria: clinical diagnosis of cardiovascular diseases (including cardiomyopathy, history of myocardial infarction, history of cardiac surgery, stent implantation, ICD implantation and so on) or secondary cardiac abnormalities due to systemic diseases.",{"count":20,"type":21},"The goal of this observational and diagnostic study is to develop and validate an artificial intelligence assisted approach for coronary computer tomography angiography-(CCTA)-based screening and diagnosis of cardiomyopathies in patients with suspected coronary artery diseases. This study aims to develop a computerized CCTA interpretation using artificial intelligence for multi-label classification task to assist cardiomyopathy diagnosis in the clinical workflow.",[73,255,256,491,492,493,102,25,103],"Restrictive Cardiomyopathy","Amyloid Cardiomyopathy","Ischemic Cardiomyopathy",[495,103,496,497],"Cardiac computer tomography angiography","Artificial intelligence","Diagnosis","2024-12-23",{"date":500,"type":51},"2024-12-27",{"date":502,"type":21},"2024-12-30",{"date":504,"type":21},"2025-12-30",{"name":506,"class":58},"Shanghai Zhongshan Hospital",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":513,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":515,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":534},"100572233","image-based-prediction-of-ventricular-tachycardias-in-post-myocarditis-patients-an-international-multicenter-case-control-study-100572233","NCT06730607","Image-Based Prediction of Ventricular Tachycardias in Post-Myocarditis Patients: an International Multicenter Case-control Study","Image-Based Prediction of Ventricular Tachycardia Events in Post-Myocarditis Patients: an International Multicenter Case-control Study","MYOCARDITIS-VT","Inclusion Criteria:\n\n1. Age \\> 18 years.\n2. Myocarditis diagnosis \\> 6 months before the inclusion in the study.\n3. Signed informed consent.\n4. CMR performed \\> 6 months after myocarditis diagnosis\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Pregnancy.\n* Other concomitant structural heart diseases (e.g. congenital, non-ischemic, etc.)\n* Active myocarditis\n* Myocarditis diagnosis \\\u003C 6 months\n* Previously documented sustained ventricular arrhythmias.\n* Impossibility or contraindications to undergo LGE-CMR.\n* Concomitant investigation treatments.\n* Medical, geographical and social factors that make study participation impractical, and inability to give written informed consent. Patient's refusal to participate in the study.",{"count":516,"type":21},150,"Ventricular arrhythmias (VAs) are frequently associated with structural heart diseases (SHD) such as myocardial infarction, myocarditis, and non-ischemic cardiomyopathies. Myocardial fibrotic tissue plays a central role in the genesis and the maintenance of re-entrant VAs associated with post-myocarditis sequelae and late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) has proven to be a useful tool for the non-invasive characterization of the scarred tissue and the underlying arrhythmogenic substrate. Moreover, a post-processing imaging platform named ADAS 3D LV (ADAS3D Medical SL, Barcelona, Spain) allows to analyze the CMR-derived data and to characterize the scar architecture, differentiating between dense (scar core zone) and more diffuse (border zone \\[BZ\\]) fibrosis, and identifying the BZ channels (BZCs) that are strands of healthy myocardial tissue within zones of unexcitable tissue and connect areas of normal myocardium. It was described that BZCs could serve as slow-conducting reentrant pathways and are critical to entail VA in ischemic and non-ischemic heart disease. However, the pathophysiological role and the correlation between scar architecture and VAs in post-myocarditis patients is yet to be defined.\n\nTo date, the standard-of-care evaluation for primary prevention implantable cardioverter-defibrillator (ICD) therapy is LVEF-based, leading to the fact that the contemporary rate of appropriated therapies is very low. Moreover, events may also occur in patients with normal to moderately depressed LVEF, which is particularly relevant, as it constitutes the most prevalent population of patients exposed to an increased risk of VAs. Multiple studies reported that LGE at CMR is a strong and specific predictor of VT occurrence and sudden death in post-myocarditis patients. There were reported cases in which even after the normalization of LVEF, the extension of LGE, the scar architecture, and the presence of BZCs at cMR analysis are determinants of the arrhythmic risk in post-myocarditis patients.\n\nThe Investigators sought to evaluate the usefulness of CMR-derived scar architecture analysis to predict the occurrence of VT events in an international, multicenter, case-control study on unselected post-myocarditis patients without previous arrhythmia evidence. Aim of the study is also to assess the net reclassification improvement (NRI) for the indication of primary prevention ICD implantation using CMR data and post-processing data as compared to LVEF-based indication",[25,519],"Ventricular Arrhythmia",[521,522,523,524],"myocarditis","ventricular arrhythmias","sudden cardiac death","cardiac magnetic resonance","2024-12-08",{"date":527,"type":51},"2024-12-12",{"date":529,"type":51},"2024-12-02",{"date":531,"type":21},"2026-12-30",{"name":533,"class":58},"Centro Medico Teknon",3,{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":543,"conditions":544,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":59},"100398171","a-10-minute-cardiovascular-magnetic-resonance-protocol-for-cardiac-disease-100398171","NCT04464655","A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease","Healthy Volunteers\n\nInclusion Criteria:\n\n* Age: \\> 18y, Informed consent No known current or pre-existing significant medical conditions that would affect the cardiovascular or respiratory system\n\nExclusion Criteria:\n\n* General MRI contraindications: MR- incompatible devices such as pacemakers, defibrillators, or implanted material or foreign bodies. Consumption of caffeinated drinks or foods (including cocoa and chocolate) during the 12 hours prior to the exam.Regular nicotine consumption during the last 6 months\n\nPatients\n\nInclusion Criteria:\n\n* Age: \\>18 y, Informed consent, Clinically indicated CMR exam\n\nExclusion Criteria:\n\n* General MRI contraindications: MR- incompatible devices such as pacemakers, defibrillators, or implanted material or foreign bodies Vasoactive medication (e.g. nitro) during the 12 hours prior to the exam. Consumption of caffeinated drinks or foods (including cocoa and chocolate) during the 12 hours prior to the exam.\n\nRegular nicotine consumption during the last 6 months",{"count":542,"type":21},2130,"This study aims to identify and assess new CMR techniques that can improve current CMR protocols.",[545,25,546,547,390,548,549,550,551,552],"Coronary Artery Disease","Infiltrative Cardiomyopathy","Dilated Cardiomyopathy","Aortic Valve Stenosis","Aortic Valve Regurgitation","Pericardial Effusion","Congenital Heart Disease","Vascular Anomaly","2024-10-22",{"date":555,"type":51},"2024-10-24",{"date":557,"type":51},"2019-12-12",{"date":559,"type":21},"2025-01-31",{"name":561,"class":58},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":462,"enrollmentInfo":570,"targetDuration":4,"studyType":136,"phases":572,"briefSummary":574,"conditions":575,"keywords":576,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":59},"100513110","phase-2-the-effects-of-hydroxychloroquine-in-patients-with-inflammatory-cardiomyopathy-100513110","NCT05961202","The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy","The Efficacy and Mechanism of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy After Myocarditis","HYPIC","Inclusion criteria:\n\n1. Male or female patient aged from 18 to 80 years;\n2. Left ventricular dysfunction \\[left ventricular ejection fraction (LVEF) \\\u003C50%\\] diagnosed by echocardiography (Simpson's biplane) within 30 days before randomization;\n3. Chronic heart failure (lasting \\>6 months) unresponsive to conventional supportive therapy;\n4. High-sensitivity cardiac Troponin I (hs-cTnI) \\>26.2 pg\u002FmL and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) \\>169pg\u002FmL;\n5. Suffered from confirmed fulminant myocarditis in the past;\n6. Diagnosed with chronic inflammatory cardiomyopathy confirmed by myocardial biopsy1;\n7. Absence of cardiotropic viruses at polymerase chain reaction analysis;\n8. Volunteer for the study and written informed consent;\n\nExclusion criteria:\n\n1. Age \\\u003C18 or \\>80 years;\n2. Acute myocardial infarction occurred within the past month;\n3. Subjects who have undergone cardiac surgery or cerebrovascular accidents within 6 months;\n4. Preparing for heart transplantation;\n5. With malignant arrhythmias such as long QT syndrome;\n6. Pregnancy or lactation;\n7. Have participated in any drug clinical trial within the three months;\n8. Presence of contraindications to prednisolone and\u002For hydroxychloroquine (including hypersensitivity to prednisone or hydroxychloroquine, mainly untreated systemic infection, uncontrolled diabetes, poorly controlled endocrine diseases, osteoporosis, gastric or duodenal ulcer, uncontrolled hypertension, leukocytopenia (leukocyte counts \\\u003C 4×109\u002FL), neutropenia (neutrophils \\\u003C 1.5×109\u002FL), thrombocytopenia (platelet levels \\\u003C 130×109\u002FL), anemia (hemoglobin levels \\\u003C 11 g\u002FdL).\n9. Confirmed or possible systemic inflammatory diseases;\n10. On the brink of death or life expectancy of less than 1 year;\n11. Drug or alcohol abuse;\n12. cannot persist in taking medication due to various reasons;\n13. Inability to provide informed consent.",{"count":571,"type":21},200,[573,138],"PHASE2","Evaluating the long-term therapeutic effects and safety of hydroxychloroquine(compared to glucocorticoid therapy alone) in patients with inflammatory cardiomyopathy--a multicenter randomized controlled study",[113,25],[577,25,578,579],"Inflammatory cardiomyopathy","Hydroxychloroquine","Randomized controlled trial","2024-10-06",{"date":582,"type":51},"2024-10-09",{"date":584,"type":51},"2021-11-01",{"date":586,"type":21},"2025-11-01",{"name":588,"class":58},"Tongji Hospital",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":97,"sex":17,"minAge":597,"maxAge":598,"enrollmentInfo":599,"targetDuration":383,"studyType":22,"phases":4,"briefSummary":601,"conditions":602,"keywords":608,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":59},"100561522","role-of-endomyocardial-biopsy-and-aetiology-based-treatment-in-pediatric-patients-with-inflammatory-heart-disease-in-arrhythmic-and-non-arrhythmic-clinical-presentations-an-integrated-approach-for-the-optimal-diagnostic-and-therapeutic-management-myoped-100561522","NCT06591260","Role of Endomyocardial Biopsy and Aetiology-based Treatment in Pediatric Patients with Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management (MYOPED)","Role of Endomyocardial Biopsy and Aetiology-based Treatment in Pediatric Patients with Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management","MYOPED","Inclusion Criteria:\n\n* Written informed consent.\n* Age \\< 18 years.\n* Clinically suspected myocarditis.\n* Enrollment performed by one of the participating Centers.\n\nExclusion Criteria:\n\n* Absence of written informed consent.\n* Age \\> 18 years (adults)","0 Years","17 Years",{"count":600,"type":21},20,"Myocarditis is a complex inflammatory disease, usually occurring secondary to viral infections, autoimmune processes or toxic agents. Clinical presentations are multiple, including chest-pain, heart failure and a broad spectrum of arrhythmias. In turn, outcome is largely unpredictable, ranging from mild self-limiting disease, to chronic stage and progressive evolution towards dilated cardiomyopathy, to rapid adverse outcome in fulminant forms. Subsequently, myocarditis is often underdiagnosed and undertreated, and optimal diagnostic and therapeutic strategies are still to be defined. This study, both retrospective and prospective, originally single-center and subsequently upgraded to multicenter, aims at answering multiple questions about myocarditis, with special attention to its arrhythmic manifestations.\n\nOptimal diagnostic workflow is still to be defined. In fact, although endomyocardial biopsy (EMB) is still the diagnostic gold standard, especially for aetiology identification, it is an invasive technique. Furthermore, it may lack sensitivity because of sampling errors. By converse, modern imaging techniques - cardiac magnetic resonance (CMR) in particular - have been proposed as alternative or complementary diagnostic tool in inflammatory heart disease. Other noninvasive diagnostic techniques, like delayed-enhanced CT (DECT) scan or position emission tomography (PET) scan, are under investigation.\n\nBiomarkers to identify myocarditis aetiology, predisposition, prognosis and response to treatment are still to be defined.\n\nArrhythmic myocarditis is largely underdiagnosed and uninvestigated. Importantly, myocarditis presenting with arrhythmias requires specific diagnostic, prognostic and therapeutic considerations. At the group leader hospital, which is an international referral center for ventricular arrhythmias management and ablation, a relevant number of patients with unexplained arrhythmias had myocarditis as underlying aetiology. The experience of a dedicated third-level center is going to be shared with other centers, to considerably improve knowledge and management of arrhythmic myocarditis.\n\nThe role of CMR, as well as alternative noninvasive imaging techniques, in defining myocarditis healing is a relevant issue. In particular, optimal timing for follow-up diagnostic reassessment is still to be defined, in patients with myocarditis at different inflammatory stages, either with or without aetiology-dependent treatment.\n\nUniformly-designed studies are lacking, to compare myocarditis among different patient subgroups, differing by variables like: clinical presentations, myocarditis stage, associated cardiac or extra-cardiac diseases, aetiology-based treatment, associated arrhythmic manifestations, diagnostic workup, and devices or ablation treatment.",[25,519,113,603,604,605,103,606,607],"Genetic Predisposition","Autoimmunity","Arrhythmia","Immunosuppresion","Catheter Ablation",[25,469,416,609,610,611,612,613,614,615,616,617,618,619,620,621],"Arrhythmogenic inflammatory cardiomyopathy","Endomyocardial biopsy","Cardiac magnetic resonance","Ablation","Positron emission tomography","Electroanatomical mapping","Immunosuppressive therapy","Arrhythmic risk stratification","Genetic predisposition","Environment","Implantable cardioverter defibrillator","Implantable loop recorder","Multicenter","2024-09-11",{"date":624,"type":51},"2024-09-19",{"date":626,"type":51},"2013-01-01",{"date":628,"type":21},"2030-12-31",{"name":479,"class":58},{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":637,"targetDuration":461,"studyType":22,"phases":4,"briefSummary":638,"conditions":639,"keywords":641,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":59},"100402555","role-of-endomyocardial-biopsy-and-aetiology-based-treatment-in-patients-with-inflammatory-heart-disease-in-arrhythmic-and-non-arrhythmic-clinical-presentations-an-integrated-approach-for-the-optimal-diagnostic-and-therapeutic-management-100402555","NCT04521790","Role of Endomyocardial Biopsy and Aetiology-based Treatment in Patients With Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management","MYOCAR","Inclusion Criteria:\n\n* Written informed consent.\n* Age ≥ 18 years.\n* Clinically suspected myocarditis.\n* Enrollment performed by one of the participating Centers.\n\nExclusion Criteria:\n\n* Absence of written informed consent.\n* Age \\\u003C 18 years (paediatric population).",{"count":99,"type":21},"Myocarditis is a complex inflammatory disease, usually occurring secondary to viral infections, autoimmune processes or toxic agents. Clinical presentations are multiple, including chest-pain, heart failure and a broad spectrum of arrhythmias. In turn, outcome is largely unpredictable, ranging from mild self-limiting disease, to chronic stage and progressive evolution towards dilated cardiomyopathy, to rapid adverse outcome in fulminant forms. Subsequently, myocarditis is often underdiagnosed and undertreated, and optimal diagnostic and therapeutic strategies are still to be defined. This study, both retrospective and prospective, originally single-center and subsequently upgraded to multicenter, aims at answering multiple questions about myocarditis, with special attention to its arrhythmic manifestations.\n\n1. Optimal diagnostic workflow is still to be defined. In fact, although endomyocardial biopsy (EMB) is still the diagnostic gold standard, especially for aetiology identification, it is an invasive technique. Furthermore, it may lack sensitivity because of sampling errors. By converse, modern imaging techniques - cardiac magnetic resonance (CMR) in particular - have been proposed as alternative or complementary diagnostic tool in inflammatory heart disease. Other noninvasive diagnostic techniques, like delayed-enhanced CT (DECT) scan or position emission tomography (PET) scan, are under investigation.\n2. Biomarkers to identify myocarditis aetiology, predisposition, prognosis and response to treatment are still to be defined.\n3. Arrhythmic myocarditis is largely underdiagnosed and uninvestigated. Importantly, myocarditis presenting with arrhythmias requires specific diagnostic, prognostic and therapeutic considerations. At the group leader hospital, which is an international referral center for ventricular arrhythmias management and ablation, a relevant number of patients with unexplained arrhythmias had myocarditis as underlying aetiology. The experience of a dedicated third-level center is going to be shared with other centers, to considerably improve knowledge and management of arrhythmic myocarditis.\n4. The role of CMR, as well as alternative noninvasive imaging techniques, in defining myocarditis healing is a relevant issue. In particular, optimal timing for follow-up diagnostic reassessment is still to be defined, in patients with myocarditis at different inflammatory stages, either with or without aetiology-dependent treatment.\n5. Uniformly-designed studies are lacking, to compare myocarditis among different patient subgroups, differing by variables like: clinical presentations, myocarditis stage, associated cardiac or extra-cardiac diseases, aetiology-based treatment, associated arrhythmic manifestations, diagnostic workup, and devices or ablation treatment.",[25,142,113,603,604,605,103,640,607],"Immunosuppression",[25,469,416,609,610,611,612,613,642,614,615,616,617,618,619,620,621],"Cardiac imaging","2024-09-07",{"date":624,"type":51},{"date":646,"type":51},"2018-01-30",{"date":648,"type":21},"2035-12-31",{"name":479,"class":58},{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":656,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":17,"minAge":70,"maxAge":462,"enrollmentInfo":658,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":660,"conditions":661,"keywords":670,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":681,"locationsCount":59},"100516173","prognosis-prediction-system-of-patients-with-cardiovascular-and-cerebrovascular-diseases-based-on-multi-omics-100516173","NCT06001073","Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics","Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics (PROSPECT): a National, Multicenter, Retrospective-prospective, Cohort Study","PROSPECT","Inclusion Criteria:\n\n* Patients who are regularly visited and followed up in the appropriate patient; department.\n* All patients met at least one of the following diagnostic criteria for cardiovascular and cerebrovascular diseases:\n* coronary artery disease group;\n* arrhythmia group;\n* heart valve disease group;\n* aortic dissection group;\n* cardiac masses group;\n* myocarditis group;\n* hypertension group;\n* cardiomyopathy group;\n* structural heart disease group;\n* ischemic cerebrovascular disease group;\n* hemorrhagic cerebrovascular disease group;\n* intracranial space occupying lesion group.\n\nExclusion Criteria:\n\n* Age \\\u003C3 years or \\>80 years old;\n* Pregnant and lactating women;\n* The patient declined to provide informed consent to participate in the study;\n* None of the above was met, but the patient was temporarily unable to sign the informed consent form due to coma and other reasons, and no legal representative signed it instead. Depending on the patient's condition, the patient may not be able to regain consciousness and sign the informed consent form.",{"count":659,"type":21},25000,"The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.",[545,662,76,663,664,25,665,103,666,667,668,669],"Arrhythmias, Cardiac","Aortic Dissection","Heart Neoplasms","Hypertension","Structural Heart Disease","Ischemic Cerebrovascular Disease","Hemorrhagic Cerebrovascular Disease","Brain Neoplasms",[671,672,673,674],"Cardiovascular diseases","Cerebrovascular diseases","Prognosis","Multi-omics","2024-07-10",{"date":677,"type":51},"2024-07-12",{"date":679,"type":51},"2022-12-05",{"date":87,"type":21},{"name":682,"class":58},"First Affiliated Hospital Xi'an Jiaotong University",{"id":684,"slug":685,"hasResults":12,"nctId":686,"briefTitle":687,"officialTitle":688,"acronym":689,"eligibilityCriteria":690,"healthyVolunteers":12,"sex":17,"minAge":70,"maxAge":462,"enrollmentInfo":691,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":692,"conditions":693,"keywords":694,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":697,"startDateStruct":698,"completionDateStruct":700,"leadSponsor":702,"locationsCount":59},"100516873","risk-stratification-value-of-biomarkers-in-patients-with-myocarditis-100516873","NCT06010199","Risk Stratification Value of Biomarkers in Patients With Myocarditis","Risk Stratification Value of Biomarkers in Patients With Myocarditis (FORWARD): a National, Multicenter, Retrospective-prospective, Cohort Study","FORWARD","Inclusion Criteria:\n\n* All patients should meet the diagnostic criteria for myocarditis\n* Patients who are regularly followed up at the corresponding cardiovascular center\n\nExclusion Criteria:\n\n* Age \\\u003C3 years or \\>80 years\n* Pregnant or lactating women\n* The patient refused to sign the informed consent and refused to participate in the study\n* None of the above is consistent, but the patient cannot sign the informed consent temporarily due to coma and other reasons, and there is no legal representative to sign it instead. Depending on the condition, the patient may not wake up to sign the informed consent",{"count":99,"type":21},"The aim of this study is to collect clinical data and biological specimens from patients with myocarditis and construct a predictive model for the prognosis of myocarditis.",[25],[25,695,696],"Biomarker","Risk stratification",{"date":677,"type":51},{"date":699,"type":51},"2023-08-25",{"date":701,"type":21},"2030-08-31",{"name":682,"class":58}]